Amgen, an international pharmaceutical company, engaged us to develop a global creative campaign related to the treatment of a rare neurological disease known as neuromyelitis optica spectrum disorder (NMOSD).The objective of this campaign was to encourage doctors to question how they view supposedly ‘stable’ disease and consider lowering their threshold for treatment failure.
